Article Contents ::
- 1 The Brand Name ACERA-FAST Has Generic Salt :: Rabeprazole
- 2 ACERA-FAST Is From Company Ipca Priced :: Rs. 33.4
- 3 ACERA-FAST have Rabeprazole is comes under Sub class GERD, of Main Class Gastrointestinal System
- 4 Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ACERA-FAST Has Generic Salt :: Rabeprazole
ACERA-FAST Is From Company Ipca Priced :: Rs. 33.4
ACERA-FAST have Rabeprazole is comes under Sub class GERD, of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Paediatric GERD
Drug Dose ::
i) Duodenal ulcer: 20 mg tablet in the morning is indicated for 4 weeks treatment in the healing and symptomatic relief of duodenal ulcer. Most patients heal within 4 weeks. ii) Benign gastric ulcer: 20 mg daily in the morning for 6 weeks, followed by a further 6 weeks if not fully cured. iii) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection: Rabeprazole in combination with Amoxicillin and Clarithromycin as a three drug regimen is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease. Rabeprazole offers a faster therapy option than other PPIs, up to 10 to 14 days 20 mg once daily. iv) Healing of erosive or ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg daily in the morning 4 to 8 weeks. Those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered. v) Treatment of symptomatic GERD: The recommended adult oral dose is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. vi) Maintenance of healing of erosive or ulcerative GERD: It is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD maintenance. Controlled studies do not extend beyond 12 months. vii) Prevention or treatment of NSAID-induced ulcers: 20 mg tablet once daily, in patients receiving treatment with NSAIDs. viii) Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg once daily and 60 mg twice daily have been administered. ix) Paediatric GERD: Treatment of GERD in Pediatric Patients 1 to 11 Years of Age: The recommended dosage for pediatric patients 1 to 11 years of age by body weight is: • Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response. • 15 kg or more: 10 mg once daily for up to 12 weeks.
Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.
Drug Precautions ::
Rabeprazole Sodium tablets should not be splited, chewed or crushed.
Drug Side Effects ::
In general, Rabeprazole is well-tolerated in both short-term and long-term studies. Rabeprazole may some times cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.
Pregnancy category ::
Drug Mode of Action ::
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell.
Drug Interactions ::
May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate. Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.